Mr. Paul Reid:

Over the course of the five years. We can give the Deputy examples of them.

We are continuously approving budgets. On the criteria that the Deputy set out in the drugs process, the team who are involved that she mentioned provide a great service for us in terms of evaluation but, obviously, Spinraza, which she mentioned, was one on which we made a decision based on the benefits in that case and how we would do it, and we have made that decision. It is one with a significant cost.

On the assessment of them over time because, as the Deputy knows well, new drugs come on board, there is an ongoing assessment of the total spend we make through the PCRS and what other drugs are coming on stream that might help us mitigate some of those costs. We have very good data from the PCRS team, in terms of drugs and the usage of them, and the distribution of them as well. There is good data. It is an ongoing process.